Literature DB >> 26994485

The Kampo medicine "Daikenchuto (TU-100)" prevents bacterial translocation and hepatic fibrosis in a rat model of biliary atresia.

Keigo Yada1, Hiroki Ishibashi2, Hiroki Mori2, Yuji Morine2, Chengzhan Zhu3, Rui Feng2, Toru Kono4, Mitsuo Shimada2.   

Abstract

BACKGROUND: Biliary atresia is the most common cause of end-stage liver disease in children. It is known that bile duct ligation contributes to liver fibrosis via bacterial translocation (BT) and toll-like receptor 4 (TLR4) signaling of hepatic stellate cells (HSCs). We have reported previously that the traditional Japanese medicine, "Dai-kenchu-to (TU-100)," a form of "Kampo medicine" prevents BT in rats exposed to the stress of fasting. The aim of this study was to clarify the effect of TU-100 on a rat model of biliary atresia using bile duct ligation.
METHODS: Bile duct ligation and subsequent daily oral administration of TU-100 was performed in 6-week-old rats. The rats were killed at 3, 7, or 14 days after bile duct ligation to evaluate the liver injury, occurrence of BT, and hepatic fibrosis. As an in vitro experiment, we isolated fresh HSCs from the rats undergoing bile duct ligation. After cell attachment, TU-100 and its 3 component herbs (eg, processed ginger, ginseng radix, and Japanese pepper) were added, and the expressions of Alpha actin2 (acta2), Alpha-1 type I collagen (colIa1), and tissue inhibitor of metalloproteinase 1 (timp1) were analyzed.
RESULTS: In vivo experiments demonstrated that oral administration of TU-100 decreased liver injury and atrophy of intestinal mucosa BT, hepatic fibrosis, and hepatic expression of alpha smooth muscle actin (αSMA) and TLR4, compared with rats that underwent bile duct ligation only. In vitro experiments showed that administration of TU-100 or the component herbs inhibited the expressions of acta2, colIa1, and timp1 in the HSCs.
CONCLUSION: TU-100 prevented BT, activation of HSCs, and subsequent hepatic fibrosis. TU-100 may prevent progression of hepatic fibrosis in children with biliary atresia and improve prognosis.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26994485     DOI: 10.1016/j.surg.2016.02.002

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  5 in total

1.  TU-100 exerts a protective effect against bacterial translocation by maintaining the tight junction.

Authors:  Chie Takasu; Wubetu Gizachew Yismaw; Nobuhiro Kurita; Kozo Yoshikawa; Hideya Kashihara; Toru Kono; Mitsuo Shimada
Journal:  Surg Today       Date:  2017-04-18       Impact factor: 2.549

2.  The inhibitory effect of TU-100 on hepatic stellate cell activation in the tumor microenvironment.

Authors:  Yuma Wada; Kazunori Tokuda; Yuji Morine; Shohei Okikawa; Shoko Yamashita; Tetsuya Ikemoto; Satoru Imura; Yu Saito; Shinichiro Yamada; Mitsuo Shimada
Journal:  Oncotarget       Date:  2020-12-08

3.  Inchinkoto, the Traditional Japanese Kampo Medicine, Enhances Intestinal Epithelial Barrier Function In Vitro.

Authors:  Ayaka Nakao; Ailing Hu; Takuji Yamaguchi; Masahiro Tabuchi; Yasushi Ikarashi; Hiroyuki Kobayashi
Journal:  Evid Based Complement Alternat Med       Date:  2022-09-29       Impact factor: 2.650

4.  Daikenchuto (Da-Jian-Zhong-Tang) ameliorates intestinal fibrosis by activating myofibroblast transient receptor potential ankyrin 1 channel.

Authors:  Keizo Hiraishi; Lin-Hai Kurahara; Miho Sumiyoshi; Yao-Peng Hu; Kaori Koga; Miki Onitsuka; Daibo Kojima; Lixia Yue; Hidetoshi Takedatsu; Yu-Wen Jian; Ryuji Inoue
Journal:  World J Gastroenterol       Date:  2018-09-21       Impact factor: 5.742

5.  Reduction in exacerbation of COPD in patients of advanced age using the Japanese Kampo medicine Dai-kenchu-to: a retrospective cohort study.

Authors:  Taisuke Jo; Nobuaki Michihata; Hayato Yamana; Yusuke Sasabuchi; Hiroki Matsui; Hirokazu Urushiyama; Akihisa Mitani; Yasuhiro Yamauchi; Kiyohide Fushimi; Takahide Nagase; Hideo Yasunaga
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-12-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.